Cinclus Pharma Holding AB (publ) (STO: CINPHA)
Sweden
· Delayed Price · Currency is SEK
20.30
0.00 (0.00%)
At close: Dec 20, 2024
Cinclus Pharma Holding AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 644.26 | 87.97 | 173.55 | 138.2 | 208.5 | 13.45 |
Cash & Short-Term Investments | 644.26 | 87.97 | 173.55 | 138.2 | 208.5 | 13.45 |
Cash Growth | 271.24% | -49.31% | 25.57% | -33.72% | 1449.96% | - |
Other Receivables | 2.92 | 3.98 | 10.23 | 1.38 | 0.17 | 0.01 |
Receivables | 2.92 | 3.98 | 10.23 | 1.38 | 0.17 | 0.01 |
Prepaid Expenses | 9.65 | 2.14 | 1.11 | 0.39 | 0.11 | 0.09 |
Other Current Assets | - | - | - | 5.38 | 3.6 | 2.36 |
Total Current Assets | 656.84 | 94.09 | 184.88 | 145.36 | 212.39 | 15.91 |
Property, Plant & Equipment | 0.88 | 0.32 | 0.89 | 1.82 | 0.02 | 0.03 |
Other Long-Term Assets | 0 | 0 | 0 | 0 | 0.07 | 0 |
Total Assets | 657.72 | 94.41 | 185.77 | 147.18 | 212.47 | 15.94 |
Accounts Payable | 10.98 | 16.45 | 16.95 | 9.19 | 5.42 | 1.37 |
Accrued Expenses | 22.97 | 6.83 | 20.47 | 7.51 | 0.64 | 2.12 |
Short-Term Debt | - | 131.01 | - | - | - | - |
Current Portion of Leases | 0.22 | 0.02 | 0.54 | 0.85 | - | - |
Current Income Taxes Payable | 7.71 | 7.22 | 5.4 | - | - | - |
Other Current Liabilities | 2.5 | 2.9 | 2.74 | 1.92 | 0.43 | 0.06 |
Total Current Liabilities | 44.38 | 164.42 | 46.1 | 19.47 | 6.49 | 3.55 |
Long-Term Leases | 0.22 | - | - | 0.61 | - | - |
Other Long-Term Liabilities | 6.87 | 6.79 | 12.8 | - | - | - |
Total Liabilities | 51.47 | 171.21 | 58.9 | 20.08 | 6.49 | 3.55 |
Common Stock | 0.9 | 0.51 | 0.51 | 0.26 | 0.26 | 0.17 |
Additional Paid-In Capital | 1,298 | 503.52 | 503.69 | 276.74 | 271.72 | 38.36 |
Retained Earnings | -718.55 | -606.84 | -394.16 | -145.08 | -68.82 | -25.88 |
Comprehensive Income & Other | 25.9 | 26 | 16.84 | -4.82 | 2.82 | -0.26 |
Shareholders' Equity | 606.25 | -76.8 | 126.87 | 127.1 | 205.99 | 12.39 |
Total Liabilities & Equity | 657.72 | 94.41 | 185.77 | 147.18 | 212.47 | 15.94 |
Total Debt | 0.44 | 131.03 | 0.54 | 1.46 | - | - |
Net Cash (Debt) | 643.82 | -43.06 | 173 | 136.75 | 208.5 | 13.45 |
Net Cash Growth | 272.15% | - | 26.51% | -34.42% | 1449.96% | - |
Net Cash Per Share | 20.15 | -1.64 | 7.51 | 6.48 | 841.82 | - |
Filing Date Shares Outstanding | 46.54 | 26.23 | 0.33 | 0.26 | 0.25 | - |
Total Common Shares Outstanding | 46.54 | 26.23 | 0.33 | 0.26 | 0.25 | - |
Working Capital | 612.46 | -70.33 | 138.78 | 125.89 | 205.9 | 12.36 |
Book Value Per Share | 13.03 | -2.93 | 387.00 | 481.30 | 831.67 | - |
Tangible Book Value | 606.25 | -76.8 | 126.87 | 127.1 | 205.99 | 12.39 |
Tangible Book Value Per Share | 13.03 | -2.93 | 387.00 | 481.30 | 831.67 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.